RxDoctor Payments Data

Courtney Weston, APRN

Family · Monroe, LANPI 1497901805

Payments from drug & device makers

$7,580in general payments, 2019–2025

Across 218 payments — averaging $34.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$797
  • Abbott$526
  • Amgen$462
  • Bayer$429
  • AbbVie$397
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$7,573100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,580 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$70,021
Medicare patients
181
Services billed
2,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$142,133
MounjaroTirzepatide99$105,617
JardianceEmpagliflozin83$70,193
EliquisApixaban74$67,126
JanuviaSitagliptin Phosphate64$50,281
GlyxambiEmpagliflozin/Linagliptin47$41,112
LinzessLinaclotide29$23,060
TradjentaLinagliptin24$22,859
KerendiaFinerenone17$20,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,546
EntrestoSacubitril/Valsartan13$17,067
Breo ElliptaFluticasone/Vilanterol25$16,709
RybelsusSemaglutide11$13,665
QuliptaAtogepant12$13,186
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$11,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$797$158,249157 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$141$134,164154 claims
Lilly USA, LLCMounjaro$298$105,61799 claims
PfizerEliquis$220$67,12674 claims
MerckJanuvia$30$50,28164 claims
GSKTrelegy Ellipta, Breo Ellipta$240$37,25555 claims
AbbVieLinzess, Qulipta$397$36,24641 claims
BayerKerendia$429$20,68717 claims
NovartisEntresto$53$17,06713 claims
AstraZenecaFarxiga$1,069$7,18313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →